Home
About us
Annual Meeting Abstracts
Annual Meeting
Annual Meeting

Annual Meeting Abstracts

25th Annual Meeting of the Japanese Society of Clinical Neuropsychopharmacology

October 29-30, 2015
KEIO PLAZA HOTEL , Tokyo, Japan

FIRST AUTHOR INDEX
First Name Last Name No. Title
Philip D. Harvey SL-1 Assessment and treatment of cognition and disability across psychiatric conditions
W. Wolfgang Fleischhacker SL-2 Pharmacological treatment of schizophrenia: Current issues and future perspectives
Hiroyuki Uchida S8-4 Antipsychotic dose and cognitive impairment
Tsuyoshi Miyaoka PJ-2 Efficacy and safety of Yokukansan in treatment-resistant schizophrenia: A Randomized, double-blind, placebo-controlled trial (A positive and negative syndrome scale, five-factor analysis)
Takashi Tsuboi EN-1 Challenging the need for sustained blockade of dopamine D2 receptor estimated from antipsychotic plasma levels in the maintenance treatment of schizophrenia: A Single-blind, randomized, controlled study
Tetsu Tomita EN-2 The Influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder
Fumihiko Ueno EN-3 Whether to increase or maintain dosage of mirtazapine in early nonimprovers with depression
W. Wolfgang Fleischhacker LS3 The management of adherence problems and the role of long-acting antipsychotics in the long-term treatment of schizophrenia
Philip D. Harvey LS5 Motivation and cognition in schizophrenia: Outcome and treatment implications
Hitoshi Sakurai O1A-1 Increasing Versus Maintaining the Dose of Olanzapine or Risperidone for Schizophrenia Patients Who Did Not Respond to Modest Dosage: A Double-Blind Randomized Controlled Trial
Takeo Saito O1A-5 Pharmacogenomic study of clozapine-induced agranulocytosis/granulocytopenia in a Japanese population
Norio Furukori O1B-3 Characteristics of escitalopram discontinuation syndrome: a preliminary study
Kazunari Yoshida O2C-6 Presence/absence of early improvement to antipsychotic treatment predicts subsequent treatment response/non-response in behavioral and psychological symptoms with dementia: Analysis of the CATIE-AD data
Shigeru Toki O2C-7 Big five personality, BIS and BAS as predictors for escitalopram treatment in patients with major depression
Miho Ota O2D-2 The effects of adjunctive intranasal oxytocin in patients with schizophrenia
Jyunichi Iga O2D-4 Association study of polymorphism in the serotonin transporter gene promoter, methylation profiles, and expression in patients with major depressive disorder
Nobutomo Yamamoto P1A-2 Inter-rater reliability and concurrent validity of the personal and social performance scale, Japanese version
Philip D. Harvey P1C-3 Dose effects for lurasidone treatment of cognitive impairments in schizophrenia
Cynthia O. Siu P1C-4 Long-term effects on daytime sleepiness and cognitive function in a 6-month, double-blind study of lurasidone and quetiapine XR in patients with schizophrenia
Hikaru Hori P1D-2 Hiccups associated with switching fron olanzapine to aripiprazole in a patient with schizophrenia
Takashi Watanabe P1E-4 Impact of CYP2D6*10 polymorphism on the pharmacokinetics of mirtazapine and its desmethylated metabolite in Japanese patients treated with mirtazapine
Mitsuhiro Tada P1E-5 Antidepressant dose and treatment response in bipolar depression: Reanalysis of the systematic treatment enhancement program for bipolar disorder (STEP-BD) data
Masaaki Ogasa P1F-3 Treatment of depressive symptoms and improved functioning in schizophrenia
Yoshiteru Takekita P1F-5 Risperidone long-acting injection versus paliperidone palmitate for cognitive function in Japanese schizophrenia: a 6-month, open-label, randomized, pilot trial.
Yoshiteru Takekita P2C-2 Effect of the HTR7 polymorphisms on perospirone and aripiprazole efficacy for Japanese schizophrenia patients
Itaru Miura P2C-4 Influence of -141C Ins/Del polymorphism in DRD2 gene on clinical symptoms and plasma homovanillic acid levels in the treatment of schizophrenia with aripiprazole


Jscnp Japanese